Meningitis Case at 2nd NJ University

View Comments (
)
|
Email
|
Print

    NEWSLETTERS

    A case of Meningitis has been reported at a second New Jersey university.

    An employee of Monmouth University in West Long Branch was diagnosed with meningococcal meningitis and has been hospitalized in very serious condition, according to a letter sent out Thursday by the school's president Dr. Paul R. Brown.

    The letter also states that the university is in touch with the Center for Disease Control and that the CDC is directing the their response to the situation.

    Meningitis Vaccine Gets Approval at Princeton

    [PHI] Meningitis Vaccine Gets Approval at Princeton
    This story was first reported on Nov. 18, 2013.
    Princeton University will follow federal recommendations and offer students an emergency, unapproved vaccine to fight an outbreak of a rare strain of meningitis. NBC10's George Spencer finds out if students will actually get the vaccine.

    Monmouth University is the second university in New Jersey to report the potentially fatal illness in less than a week.

    Princeton University decided on Monday to administer a meningitis vaccine that hasn't been approved in the U.S. after a seventh case was reported. The doses will be available to undergraduate and graduate students who live on campus, as well has employees suffering from certain medicial conditions.

    Teen Survives Life-Threatening Meningitis, Returns Home

    [LA] Teen Survives Life-Threatening Meningitis, Returns Home
    A 19 year-old Orange County woman who was told she would not make it through the week is spending her first night at home in almost eight months. Kaitlyn Dobrow went to the hospital believing she had the flu and learned she contracted bacterial meningitis, a severe infection that has taken both her arms and legs. Vikki Vargas reports from Huntington Beach for the NBC4 News at 5 p.m. on Oct. 3, 2013.

    The CDC says the outbreak at Princeton is the first in the world since the vaccine against the type B meningococcal bacteria was approved in Europe and Australia this year, the only one for use against the strain. The vaccine is in the approval process in the U.S.

    Related News: